Found: 15
Select item for more details and to access through your institution.
Relationship between T cell receptor clonotype and PD‐1 expression of tumor‐infiltrating lymphocytes in colorectal cancer.
- Published in:
- European Journal of Immunology, 2020, v. 50, n. 10, p. 1580, doi. 10.1002/eji.201948399
- By:
- Publication type:
- Article
IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 10, p. 5726, doi. 10.3390/ijms23105726
- By:
- Publication type:
- Article
Development of INSOL‐tag for proteome‐wide protein handling and its application in protein array analysis.
- Published in:
- Genes to Cells, 2020, v. 25, n. 1, p. 41, doi. 10.1111/gtc.12735
- By:
- Publication type:
- Article
MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy.
- Published in:
- Diabetologia, 2015, v. 58, n. 6, p. 1309, doi. 10.1007/s00125-015-3564-1
- By:
- Publication type:
- Article
Interleukin-21 Is a Critical Regulator of CD4 and CD8 T Cell Survival during Priming under Interleukin-2 Deprivation Conditions.
- Published in:
- PLoS ONE, 2014, v. 9, n. 1, p. 1, doi. 10.1371/journal.pone.0085882
- By:
- Publication type:
- Article
Intratumoral Injection of Propionibacterium acnes Suppresses Malignant Melanoma by Enhancing Th1 Immune Responses.
- Published in:
- PLoS ONE, 2011, v. 6, n. 12, p. 1, doi. 10.1371/journal.pone.0029020
- By:
- Publication type:
- Article
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 11, p. 3081, doi. 10.1007/s00262-021-02892-w
- By:
- Publication type:
- Article
First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 4, p. 663, doi. 10.1007/s00262-020-02483-1
- By:
- Publication type:
- Article
A phase 1 trial of NY‐ESO‐1‐specific TCR‐engineered T‐cell therapy combined with a lymph node‐targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 12, p. 2554, doi. 10.1002/ijc.34453
- By:
- Publication type:
- Article
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
- Published in:
- 2019
- By:
- Publication type:
- journal article
First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer.
- Published in:
- Case Reports in Oncology, 2019, v. 12, n. 1, p. 147, doi. 10.1159/000496933
- By:
- Publication type:
- Article
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Serum immunoglobulin E response as a marker for unfavorable prognosis following cholesteryl pullulan-MAGE A4 vaccination.
- Published in:
- Oncology Letters, 2018, v. 15, n. 3, p. 3703, doi. 10.3892/ol.2018.7767
- By:
- Publication type:
- Article
Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel.
- Published in:
- Oncology Letters, 2016, v. 12, n. 6, p. 4493, doi. 10.3892/ol.2016.5253
- By:
- Publication type:
- Article